Nuvation Bio Inc.
Heterocyclic compounds as adenosine antagonists
Last updated:
Abstract:
5,6-disubstituted 2-aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
Status:
Grant
Type:
Utility
Filling date:
17 Jan 2020
Issue date:
19 Apr 2022